Odds are 90% in favor of favorable CLSN Phase III top line results... it's not the drug rather a delivery system being tested... it's known to work in previous testing. (insider buying)
When FDA approval is granted, the potential market opportunity for CLSN is at least $1 billion. that's $30 a share instantly maybe lots more with that FDA approval. Stocks have gone to $40's or $50's on like news. With phase III results in Jan. $24 is a reasonable price expectation. $12 before news making odds an even bet as they say however it's not 50% odds more like 90% so in reality $12 is still cheap in Jan pre news.
CLSN last reported short interest: 5,541,000 and short ratio of 7.1 That's a lot of buying to cover and we all know short squeezes run stocks up hard as it's completed on top of already heavier than average buying.